Aprea Therapeutics to Provide Update on Precision Oncology Focus
Aprea Therapeutics, Inc. (NASDAQ: APRE), an innovative clinical-stage biopharmaceutical company, has announced that its President and Chief Executive Officer, Oren Gilad, Ph.D., will deliver a significant corporate update. This presentation is set to take place at the prestigious H.C. Wainwright Annual Global Investment Conference, a key event for investment professionals where industry leaders share valuable insights and developments.
Investor Event Details
The H.C. Wainwright Annual Global Investment Conference will serve as an important platform for Aprea Therapeutics. While specific location details are not disclosed, the conference will span three days. For those unable to attend in person, webcasting will be available, allowing access to the presentation “on-demand.” This feature enhances engagement for both investors and analysts. Additionally, Aprea’s leadership team will conduct one-on-one meetings with institutional investors during the conference, facilitating in-depth discussions about future initiatives.
About Aprea Therapeutics
Aprea Therapeutics stands out for its commitment to precision oncology, leveraging synthetic lethality as an innovative treatment approach. The company focuses on developing therapies that target specific elements of cancer cell biology. Aprea’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor designed to treat solid tumor indications. Furthermore, the company is advancing APR-1051, an oral small molecule WEE1 inhibitor that has recently entered clinical trials.
Advancements in Cancer Treatment
Aprea's cutting-edge strategies in cancer treatment highlight the significance of personalized medicine. The therapies under development aim not only to enhance patient outcomes but also to provide targeted treatments that reduce side effects when compared to traditional therapies. By concentrating on specific genetic mutations and vulnerabilities within cancer cells, Aprea Therapeutics is leading the charge in creating next-generation cancer therapies.
Engaging Investors and Raising Awareness
Aprea Therapeutics invites interested investors and stakeholders to explore its strategic direction. The company actively shares updates through its investor relations website, ensuring transparency and adherence to regulatory standards. This platform provides crucial information regarding clinical advancements, corporate strategies, and market insights.
Contact Information for Stakeholders
For any inquiries, stakeholders can directly reach out to the investor relations contact:
Mike Moyer
LifeSci Advisors
Email: mmoyer@lifesciadvisors.com
For media inquiries, Aprea has provided contact options to facilitate communication:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Email: Ignacio.guerrero-ros@russopartnersllc.com
Email: David.schull@russopartnersllc.com
Frequently Asked Questions
What is Aprea Therapeutics focused on?
Aprea Therapeutics is dedicated to precision oncology, employing innovative therapeutic strategies centered around synthetic lethality.
When will the corporate update be available?
The corporate update will be accessible “on-demand” starting at 7:00 A.M. (ET) on the days of the conference.
What are Aprea's lead programs?
Aprea's lead programs consist of ATRN-119, a small molecule ATR inhibitor, and APR-1051, a WEE1 inhibitor.
How can investors stay informed about Aprea's developments?
Investors can remain updated by visiting the company's investor relations website for regular information on clinical developments and corporate strategies.
Who is available for one-on-one meetings during the conference?
Aprea’s management team will be available for one-on-one meetings with institutional investors throughout the duration of the conference.
